All systems operational
For Researchers
For Publishers
Login
Register
عربي
Submit Journal
عربي
Navigation
01
Discover
02
Rankings
03
For Publishers
04
About AMS
Back to Menu
Discover
By type
Journals
Research Papers
Authors
Institutions
Publishers
Affiliates
By Field
Medicine & Health Sciences
Engineering & Technology
Natural Sciences
Social Sciences
Computer Science & AI
All 98 fields →
By Country
🇸🇦 Saudi Arabia
🇪🇬 Egypt
🇯🇴 Jordan
🇦🇪 UAE
🇲🇦 Morocco
All 22 countries →
Tools
DOI Lookup
ISSN Search
Rankings
Journal rankings
AMS Score Ranking
Citation Impact (CIF)
Quartile Rankings Q1–Q4
Open Access Index
Rising Stars
People & places
Authors Ranking
Institutions Ranking
Country Ranking
By subject
Medicine & Health
Engineering
Computer Science
Natural Sciences
All rankings →
For Publishers
Get indexed
Journal Indexing
Indexing Criteria
Packages & Pricing
Review Timeline
Benefits
Global visibility — 22 countries
AMS Score badge
AMS Certification
Real-time analytics dashboard
REST API access
Resources
Publisher Sign In
Register
API Documentation
Publisher FAQ
About AMS
Platform
What is AMS?
Our Methodology
Quality Standards
News & Updates
Technical
API Documentation
Data Sources
System Status
Resources
Research Reports
Annual Statistics
Press Kit
FAQ
Contact Us
Login
Register
Affiliates
For Researchers
Submit Journal
Home
Authors
Mahmoud Aljurf
MA
Mahmoud Aljurf
h-8
H-Index
199
Citations
19
Papers
Published Papers
19 indexed
1
The Risk and Prognosis of COVID-19 Infection in Cancer Patients
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.1016/j.hemonc.2020.07.005
80
citations
396
2
Hepatitis-Associated Aplastic Anemia
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.1016/j.hemonc.2020.10.001
24
citations
387
3
Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1048
16
citations
389
4
Diagnosis and Treatment of Subcutaneous Panniculitis-like T-cell Lymphoma: A Systematic Literature Review
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.1016/j.hemonc.2021.04.001
15
citations
390
5
Hematologic Manifestations of Parvovirus B19 Infection
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.56875/2589-0646.1031
12
citations
390
6
Next-Generation Chimeric Antigen Receptor T-cells
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1035
11
citations
385
7
Infectious Complications and Preventative Strategies following Chimeric Antigen Receptor T-cells (CAR-T cells) Therapy for B-Cell Malignancies
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1049
10
citations
387
8
CAR-T cell Therapies for B-cell Lymphoid Malignancies
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1026
9
citations
388
9
Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.56875/2589-0646.1108
6
citations
391
10
Current Practice of Oral Care for Hematopoietic Stem Cell Transplant Patients: A Survey of the Eastern Mediterranean Blood and Marrow Transplantation Group
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.1016/j.hemonc.2021.01.006
5
citations
394
11
H syndrome: A histiocytosis-lymphadenopathy plus syndrome. A comprehensive review of the literature
Hematology/Oncology and Stem Cell Therapy
Q3
2024
10.4103/hemoncstem.hemoncstem-d-24-00004
5
citations
390
12
Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1025
3
citations
389
13
Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature
Hematology/Oncology and Stem Cell Therapy
Q3
2024
10.4103/hemoncstem.hemoncstem-d-24-00034
2
citations
387
14
Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients
Annals of Saudi Medicine
Q1
2024
10.5144/0256-4947.2024.93
1
citations
2,140
15
Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.1016/j.hemonc.2020.04.003
0
citations
391
16
Framework for Patient Advocacy in Hematopoietic Cell Transplantation (HCT): An Overview from the Worldwide Network for Blood and Marrow Transplantation
Hematology/Oncology and Stem Cell Therapy
Q3
2025
10.4103/hemoncstem.hemoncstem-d-24-00054
0
citations
392
17
Cancer epidemiology in the Kingdom of Saudi Arabia, 2024
Hematology/Oncology and Stem Cell Therapy
Q3
2026
10.4103/hemoncstem.hemoncstem-d-26-00008
0
citations
393
18
Progressive transformation of germinal centers: Bridging clinical and pathological insights for diagnostic precision
Hematology/Oncology and Stem Cell Therapy
Q3
2026
10.4103/hemoncstem.hemoncstem-d-25-00052
0
citations
389
19
Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Hematology/Oncology and Stem Cell Therapy
Q3
2026
10.4103/hemoncstem.hemoncstem-d-26-00018
0
citations
387
Publication Activity
Journals Published In
ASM
Annals of Saudi Medicine
🇸🇦
Q1
AMS 90
HOST
Hematology/Oncology and Stem Cell Therapy
🇸🇦
Q3
AMS 72